| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/26/2002 | CA2441291A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/26/2002 | CA2441202A1 Chemical compounds |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2440954A1 Phenyl derivatives 3 |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | CA2425902A1 Urocortin-iii and uses thereof |
| 09/26/2002 | CA2404581A1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 09/25/2002 | EP1243652A2 Glial derived neurotrophic factor |
| 09/25/2002 | EP1243581A1 Pyridinium compounds useful for the treatment of AGE-related diseases |
| 09/25/2002 | EP1243269A2 Opioid formulations having extended controlled release |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1243263A1 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| 09/25/2002 | EP1243262A1 Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| 09/25/2002 | EP1242822A2 Methods of detection of amyloidogenic proteins |
| 09/25/2002 | EP1242624A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242458A2 Brain specific binding members |
| 09/25/2002 | EP1242432A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 09/25/2002 | EP1242431A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 09/25/2002 | EP1242423A1 SUBSTITUTED 1,2,3-TRIAZOLO 1,5-a]QUINAZOLINES FOR ENHANCING COGNITION |
| 09/25/2002 | EP1242422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242411A1 Indole derivatives for the treatment of depression and anxiety |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242404A1 Phenoxypropanolamines, preparation and therapeutic use thereof |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242402A2 Novel compounds |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242398A2 Partially saturated calcium channel blockers |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242394A1 Novel 3-oxo-2,1-benzisoxazol-1(3h)-carboxamides for treatment of cns diseases |
| 09/25/2002 | EP1242389A2 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242383A1 Aza compounds having neuronal activity |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242381A2 2-phenyl-quinoline derivatives, preparation method and therapeutic use thereof |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242120A2 Combinations of growth factors and i:upa or i:mmp for the treatment of damaged tissue |
| 09/25/2002 | EP1242118A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 09/25/2002 | EP1242109A2 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t |
| 09/25/2002 | EP1242105A2 Combination of ginseng and ginkgo to improve cognitive skills |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242094A1 Methods for treating mild cognitive impairment |
| 09/25/2002 | EP1242093A1 A method of treating substance addiction |
| 09/25/2002 | EP1242092A2 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 09/25/2002 | EP1242091A2 Pharmaceutical compositions comprising oxcarbazepine |
| 09/25/2002 | EP1242089A2 Use of adatanserin for the treatment of neurodegenerative conditions |
| 09/25/2002 | EP1242088A1 Oral mucosal dosage forms of apomorphine |
| 09/25/2002 | EP1242087A2 Analgesic compositions containing buprenorphine |
| 09/25/2002 | EP1242085A1 Benzimidazole compounds having nociceptin receptor affinity |
| 09/25/2002 | EP1242083A1 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them |
| 09/25/2002 | EP1242081A1 Caspases and apoptosis |
| 09/25/2002 | EP1242078A2 Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 09/25/2002 | EP1242076A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 09/25/2002 | EP1242074A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 09/25/2002 | EP1242072A1 Antipsychotic heterocycle compounds |
| 09/25/2002 | EP1242069A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 09/25/2002 | EP1242068A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 09/25/2002 | EP1242066A1 Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
| 09/25/2002 | EP1242063A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 09/25/2002 | EP1242061A2 Use of bioactive metabolites of gepirone for the treatment of psychological disorders |
| 09/25/2002 | EP1242054A2 Odor-masking coating for a pharmaceutical preparation |
| 09/25/2002 | EP1242053A1 Apparatus and method for preparing microparticles using in-line solvent extraction |
| 09/25/2002 | EP1241935A2 Methods for producing transgenic animals |
| 09/25/2002 | EP1157020B1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, method for producing them and their use as medicaments |
| 09/25/2002 | EP1144408B1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application |
| 09/25/2002 | EP1073651B1 Indolyl derivatives as serotonergic agents |
| 09/25/2002 | EP1067905B1 Fizzy formulations |
| 09/25/2002 | EP0994710B1 Pharmaceutical compositions for oral administration, comprising a benzhydrylpiperazine and a cyclodextrin |
| 09/25/2002 | EP0986390B1 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 09/25/2002 | EP0972020B1 Insulin-like growth factor agonist molecules |
| 09/25/2002 | EP0942751B1 Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
| 09/25/2002 | EP0931081B1 Pyridazino 4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 09/25/2002 | EP0925299B1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 09/25/2002 | EP0923550B1 Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists |
| 09/25/2002 | EP0918521B1 Formulation for the treatment and/or prophylaxis of dementia |
| 09/25/2002 | EP0912534B1 Muscarinic antagonists |
| 09/25/2002 | EP0912184B1 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
| 09/25/2002 | EP0907635B1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| 09/25/2002 | EP0904087B1 Phosphatidic acid-comprising compositions |
| 09/25/2002 | EP0841928B1 Sustained-release formulation of d-threo-methylphenidate |
| 09/25/2002 | EP0746556B1 Tricyclic compounds having affinity for the 5-ht1a receptor |
| 09/25/2002 | EP0702551B1 Compositions and methods for reparation and prevention of fibrotic lesions |
| 09/25/2002 | CN1371424A Activatable recombinant neurotoxins |
| 09/25/2002 | CN1371416A Human CTLA-4 antibodies and their uses |
| 09/25/2002 | CN1371390A Human G-protein coupled receptor |